Insider filing · DNLI
Steve E. Krognes
Director
profile →
Steve E. Krognes sold $608K of Denali Therapeutics (DNLI)
Executed Dec 31 2024, disclosed Jan 3 2025, 3 days later.
Value, as filed
$608K
30,000 sh × $20.25
Executed
Dec 31 2024
the trade date, as filed
Disclosed
Jan 3 2025
3 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
SKSteve E. Krognes (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Guardant Health, Inc. (GH). The largest single filing was $1.2M of GH (9,294 sh × $132.51, as filed), executed Jun 4.
The name
DNLI
Denali Therapeutics Inc.
DNLI · Healthcare · 10 filings in 24 months
ticker →
Healthcare · Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→